James Ward-Lilley, CEO of Vectura, commented:
“We are pleased that Novartis has signed this licensing agreement with Sunovion to bring Seebri and Utibron to the US market. We are confident that with its established US respiratory focus and commercialisation expertise Sunovion will be a strong partner. The launch of these products in 2017 will give doctors new treatment options for their COPD patients. We look forward to the successful US commercialisation of these products and the further contribution they will make to the substantial existing recurring and growing royalty stream we receive from Novartis as reported in our recent interim results.”
The scope of the opportunity using the Heptares approach extends well beyond our growing Pipeline.
・2016.03実：売上高 8,151 営業利益 1,075 経常利益-3,297 当期利益-1,432 １株益-93.6
・2017.03予：売上高19,400 営業利益12,400 経常利益11,000 当期利益9,800 １株益579.4
・2018.03予：売上高16,000 営業利益 7,000 経常利益 6,000 当期利益4,000 １株益236.5
※HuffingtonPost: Women in Business Q&A: Dr Fiona Marshall: We were very fortunate to be acquired by the Japanese company Sosei Group. (3/18)
・Several of the drugs we are developing at Heptares are expected to be tested in patients during the next year - this includes drugs for Alzheimers disease and cancer.
※HeptaresTL: We are seeking an Analytical Scientist. Experience of state-of-the-art automated reverse phase hplc analytical. "Closing 25 April 2017" (3/20)
※Vectura: Preliminary Results for the nine-month period ended 31 Dec: Net sales of Ultibro Breezhaler grew 37% over the period, benefiting from FLAME data. (3/21)
・The Group anticipates US sales will generate a further contribution to the substantial and growing recurring royalty stream it receives from Novartis.
※Vectura Groups CEO James Ward-Lilley on Preliminary Results for 9 month period ended 31 December 2016 - Earnings Call. (3/21)
・We expect Ultibro and Seebri to be launched by Novartis in the U.S. partners Sanofi during 2017.
・Sales of Seebri and Ultibro with over $500 million for the year and that compares to Novartis Analyst peak sales expectation of around the billion dollar mark in the 2022 timeframe, they were about half way to peak sales.
・In addition, we expect revenues from the US launches of Seebri and Ultibro.
・QVM149: Being developed by Novartis clearly building strongly on each enrollment after Ultibro performance ex-US,
・we think was a very strong opportunity for this asset in phase 3, we should see that product coming into market in 2020.
・Novartis has the opportunity to be potentially one of the first DPI triple therapies coming in Asthma segments in Europe.
※Conference Report: The 13th Winter Conference on Medicinal and Bioorganic Chemistry. (First published: 22 March 2017)
・This conference report summarizes the presentations that were given this year (January 22 nd - 26 th).
・Giles Brown (Heptares) followed with his talk on structure-based drug design with GPCRs and the discovery of highly selective muscarinic M1 receptor agonists.
・Using the M1 receptor StaR protein in conjunction with structure-based drug design, Brown detailed how Heptares researchers were able to identify a lead molecule and eventually optimize this into a compound (HTL9936) which targets the M1 receptor and is currently in phase 1a/1b studies for the treatment of AD.